106 related articles for article (PubMed ID: 26036797)
1. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
2. Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.
Secore S; Wang S; Doughtry J; Xie J; Miezeiewski M; Rustandi RR; Horton M; Xoconostle R; Wang B; Lancaster C; Kristopeit A; Wang SC; Christanti S; Vitelli S; Gentile MP; Goerke A; Skinner J; Strable E; Thiriot DS; Bodmer JL; Heinrichs JH
PLoS One; 2017; 12(1):e0170640. PubMed ID: 28125650
[TBL] [Abstract][Full Text] [Related]
3. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
Hussack G; Tanha J
Toxins (Basel); 2010 May; 2(5):998-1018. PubMed ID: 22069622
[TBL] [Abstract][Full Text] [Related]
4. Isofagomine Inhibits Multiple TcdB Variants and Protects Mice from
Paparella AS; Brew I; Hong HA; Ferriera W; Cutting S; Lamiable-Oulaidi F; Popadynec M; Tyler PC; Schramm VL
ACS Infect Dis; 2024 Mar; 10(3):928-937. PubMed ID: 38334357
[No Abstract] [Full Text] [Related]
5. Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects.
Di Bella S; Ascenzi P; Siarakas S; Petrosillo N; di Masi A
Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27153087
[TBL] [Abstract][Full Text] [Related]
6. The glucosyltransferase activity of C. difficile Toxin B is required for disease pathogenesis.
Bilverstone TW; Garland M; Cave RJ; Kelly ML; Tholen M; Bouley DM; Kaye P; Minton NP; Bogyo M; Kuehne SA; Melnyk RA
PLoS Pathog; 2020 Sep; 16(9):e1008852. PubMed ID: 32960931
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of Clostridium difficile toxin A.
Chumbler NM; Rutherford SA; Zhang Z; Farrow MA; Lisher JP; Farquhar E; Giedroc DP; Spiller BW; Melnyk RA; Lacy DB
Nat Microbiol; 2016 Jan; 1():15002. PubMed ID: 27571750
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Fusion Protein Vaccine Containing Clostridioides difficile FliC and FliD Protects Mice against C. difficile Infection.
Wang S; Ju X; Heuler J; Zhang K; Duan Z; Warnakulasuriya Patabendige HML; Zhao S; Sun X
Infect Immun; 2023 Apr; 91(4):e0016922. PubMed ID: 36939332
[TBL] [Abstract][Full Text] [Related]
9. Towards Development of a Non-Toxigenic
Hughes J; Aston C; Kelly ML; Griffin R
Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631671
[No Abstract] [Full Text] [Related]
10. Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.
Wang S; Zhu D; Sun X
Microbiol Spectr; 2022 Jun; 10(3):e0026322. PubMed ID: 35583336
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the treatment of
Giau VV; Lee H; An SSA; Hulme J
Infect Drug Resist; 2019; 12():1597-1615. PubMed ID: 31354309
[No Abstract] [Full Text] [Related]
12. Novel Chimeric Protein Vaccines Against
Wang S; Wang Y; Cai Y; Kelly CP; Sun X
Front Immunol; 2018; 9():2440. PubMed ID: 30405630
[No Abstract] [Full Text] [Related]
13. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
[TBL] [Abstract][Full Text] [Related]
14. Bioprospecting Deep-Sea Actinobacteria for Novel Anti-infective Natural Products.
Xu D; Han L; Li C; Cao Q; Zhu D; Barrett NH; Harmody D; Chen J; Zhu H; McCarthy PJ; Sun X; Wang G
Front Microbiol; 2018; 9():787. PubMed ID: 29760684
[TBL] [Abstract][Full Text] [Related]
15.
Zhu D; Sorg JA; Sun X
Front Cell Infect Microbiol; 2018; 8():29. PubMed ID: 29473021
[No Abstract] [Full Text] [Related]
16. Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against
Liu YW; Chen YH; Chen JW; Tsai PJ; Huang IH
Front Microbiol; 2017; 8():1411. PubMed ID: 28790999
[No Abstract] [Full Text] [Related]
17. A Detrimental Role of Immunosuppressive Drug, Dexamethasone, During Clostridium difficile Infection in Association with a Gastrointestinal Microbial Shift.
Kim HB; Wang Y; Sun X
J Microbiol Biotechnol; 2016 Mar; 26(3):567-71. PubMed ID: 26809802
[TBL] [Abstract][Full Text] [Related]
18. A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters.
Wang YK; Yan YX; Kim HB; Ju X; Zhao S; Zhang K; Tzipori S; Sun X
Hum Vaccin Immunother; 2015; 11(9):2215-22. PubMed ID: 26036797
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
